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Hepatocellular carcinoma (HCC) is
one of the most common cancers in
the world. It is a growing public
health problem and its incidence is
increasing worldwide (most cases of
HCC in Asia and sub-saharan Africa
but recently, in western countries
too (1, 2)). The presence of cirrhosis
is the major risk factor, essentially
due to chronic hepatitis C and hepa-
titis B infection or alcohol dis-
ease (1). Hepatocellular carcinoma is
of poor prognosis: the five-year sur-
vival rate is less than 5 percent (2).
The prognosis depends on hepatic
function, tumour size, and tumour
extent at the time of diagnosis.
Nowadays, orthotopic liver trans-
plantation only remains curative, but
because of the shortage of organ
donors, these treatments are appli-
cable only to a small part of all
patients. The majority of the patients
with unresectable HCC are treated
by various palliative therapies
included surgical resection (partial
hepatectomy), or percutaneous
treatment. Despite advances in
imaging techniques and follow-up
programs only 20% of patients are
candidates for surgery at the time of
diagnosis (3, 4) due to an advanced
tumor stage, comorbidities, poor
hepatic functional reserve or short-
age of donor livers. 
Case report
A 78-year-old man was referred to
our hospital in September 2008 for a
health deterioration associated with
weight loss. His medical history was
CT-guided biopsy of the largest
hepatic lesion (segment IV) con-
firmed the diagnosis of well differen-
tiated HCC in a cirrhotic liver. The
patient was medically treated.
On a follow-up CT scan, a few
months later, it appeared that the
segment IV mass was markedly
increased (6 × 5.5 × 7 cm) (Fig. 1A).
The segment II and VI lesion were
confirmed but stable. Additional
tests did not reveal any metastasis.
After multidisciplinary consensus
and given the patient’s delicate clini-
cal condition, surgical treatment was
not adequate. In these conditions,
the presence of multiple liver HCC
nodules justified a transarterial
chemoembolization (TACE). TACE
was performed with no intra-opera-
tive complications. Embolization of
the feeding artery was performed
with small gelfoam pledgets before
(to reduce the flow) and after (to
achieve stases) injection of 50 mg of
cisplatine (Fig. 1B and C). Post -
operative and one week control CT-
scan (Fig. 2) didn’t show any sign of
active arterial contrast extravasation
and other complications.
Three weeks after transarterial
chemoembolization (TACE), the
patient complained about a right
upper abdominal pain. This led to an
abdominal CT-Scan (Fig. 3) that
revealed ruptured necrotic mass
with associated peritonitis and
pneumo peritoneum but no active
bleeding. At this time, laboratory test
revealed stable anemia (haemoglo-
bin level: 10.9 g/dl), hypoalbumine-
mia (19 g/l), abnormal liver function
tests (ALP/GGT: 359/168 IU/L) and
elevated conjugated bilirubin level
(5.2 mg/L). 
Because of the bad general state
of the patient, conservative treat-
ment was decided with discharge
from hospital to palliative care.
Unfortunately, the patient died two
months after TACE procedure.
remarkable for silicosis associated
with respiratory failure, type 2 dia-
betes and cerebrovascular accident.
He had a previous history of smok-
ing and persistent alcohol abuse was
documented. On admission, his
height was 165 cm and his body
weight 74 kg. There was no history of
hematemesis, vomiting, flushing or
diarrhea.
Clinical examination revealed a
hepatomegaly without
splenomegaly. Jaundice, ascites,
peripheral oedema and other signs
of chronic liver disease were not
observed. The patient’s blood pres-
sure was 120/60 mmHg and heart
rate was regular to 74 beats per
minute. Laboratory test revealed
marked leukocytosis (18000/mm3),
hemoglobin level 11g/dl and abnor-
mal liver function tests (ALP/GGT:
125/158 IU/L). Serum tumor markers
were within normal range (-fetopro-
tein: 2.6 ng/ml). Other laboratory
tests were also within normal range.
However, glycaemia (110 mg/dl) and
HbA1c (7.9%) were slightly elevated.
Tests for hepatitis B and C virus
markers were all negative. The
patient showed a Child-Pugh score
of 7 (class B).
A triphasic contrast enhanced CT-
scan showed three hypervascular
lesions, without clear wash out, sus-
pected of malignancy. The bigger
one was in segment IV (4 × 4 cm)
and near to the liver capsule. The
other lesions were localized in seg-
ment II and in segment VI.
Ultrasound was not contributive
because of patient’s corpulence. A
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function. Tumor sizes, hypovasculari-
ty on imaging and elevated INR are
predictors of increased mortality
after TACE therapy for HCC (13).
Contraindications for TACE (19)
include portal vein thrombosis, sig-
nificant arteriovenous shunting and
poor liver function (Child-Pugh class
C).
Imaging techniques and correct
anatomical evaluation is essential to
select those patients who may poten-
tially benefit from the procedure. CT
or MR examinations should be done
prior to TACE (8). Although mean
 survival rates of 12 months (13) have
been reported, a variety of complica-
tions have been described after TACE
with significant morbidity. These
complications are more often benign
and include postembolization syn-
drome (fever, abdominal pain, nau-
sea, and vomiting), impaired liver
function, and leukocytopenia (3, 5,
14). However major complications
are described. Liver failure, as well
as liver abscess, splenic infarction,
treatment of choice (7). TACE com-
bines the effect of targeted
chemotherapy with the effect of
ischemic necrosis induced by arterial
embolization (8). The basic principles
of the procedure consist of a reduc-
tion of hepatic arterial blood supply
to the tumor as well as the delivery
of cytostatic agents (Adryamycin,
Cisplatin, or Doxorubicin) directly
into the tumor. It is well known that
HCC is hypervascularised (with a
high propensity for vascular inva-
sion and growth factor produce) and
that this hypervascularisation is
mostly dependent on the hepatic
artery and its branches (9).
The survival benefit of this treat-
ment is confirmed by two meta-
analyses (10, 11) and two recent ran-
domized controlled trials (4, 12) that
allowed showing a significant higher
survival rate compared to a group of
best supportive care after three
years. However its benefice appears
only in selected patients with unre-
sectable HCC and preserved liver
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Fig. 1. — A: Coronal Multi-Planar Reconstruction (MPR) of a contrast enhanced CT scan of arterial phase demonstrates a hyper -
enhancing lesion in segment IV. B: Hepatic angiography (arteriogram) shows an anarchic hypervascularised hepatic mass that
 suggests hepatocellular carcinoma with formation of arteriovenous shunts. C: Hepatic angiography after chemoembolization shows




Fig. 2. — Contrast enhanced CT scan
obtained one week after TACE shows the
integrity of the liver capsule.
Fig. 3. — Axial (A and B) and sagittal (C) contrast enhanced CT scan, in arterial phase, obtained 3 weeks after TACE shows a
 capsular rupture at the level of the necrotic mass with associated peritonitis and pneumoperitoneum.
Discussion
Transarterial chemoembolization
(TACE) is an efficient palliative well
accepted treatment for unresectable
HCC (3, 5, 6). In the presence of mul-
tiple HCC nodules, TACE remains the
upper gastrointestinal bleeding, bile
duct complications, acalculous
cholecystitis, pulmonary embolism,
spasm or occlusion of hepatic artery
and acute renal failure are associat-
ed with significant morbidity and
mortality.
Rupture following TACE is uncom-
mon and represents less than 1% of
all complications (15) but it is proba-
bly the most important complication
of TACE with an extremely poor
prognosis (1). The mortality and
morbidity rate is high because the
patients usually suffer from an
advanced disease. 
The mechanism of rupture of HCC
after TACE is unclear. It is probably to
be related to tumor and capsular
necrosis and increased pressure
inside the friable tumor after TACE.
Secondary infection, vascular injury
during TACE or inflammation sec-
ondary to the chemotherapeutic
agents could play a role too (1). They
can appear especially when there is
no tumor capsule or when the lesion
is located adjacent to the Glissonian
liver capsule (16). Two series from
Asia conclude that most patients
with complications after TACE had
pre-existing risk factors as large
tumor size, or extracapsular exten-
sion of the tumor (15, 17).
Patients with ruptured hepatocel-
lular carcinoma present right upper
abdominal pain and abdominal dis-
tension and the diagnosis is usually
confirmed by US or CT-Scan. CT
imaging is the most useful modality
in the imaging of HCC (18) and can
detect most of complications follow-
ing TACE (18). In a ruptured HCC,
blood or gas (as a result of necrosis)
may be seen in the lesion, around
the liver or within the peritoneal cav-
ity. Bleeding may also occasionally
be seen. 
Management of patients with rup-
ture of HCC following TACE is diffi-
cult and remains controversial
because patients have already been
diagnosed as having inoperable
tumor and poor liver function. The
primary objective in the manage-
ment of these patients is to control
potential bleeding and to maintain
haemodynamic parameters stables.
Hemostasis can be done by surgical
laparotomy, interventional or con-
servative methods. Battula et al (19)
consider that a repeat TACE can be
7. Acunas B., Rozanes I.: Hepatocellular
carcinoma: treatment with tran-
scatheter arterial chemoembolization.
Eur J Radiol, 1999, 32:86-89.
8. Shin S.W.: The current practice of
transarterial chemoembolization for
the treatment of hepatocellular carci-
noma. Korean J Radiol, 2009, 10: 425-
434.
9. Nakashima T., Kojiro M.: Pathologic
characteristics of hepatocellular carci-
noma. Semin Liver Dis, 1986, 6: 259-
266.
10. Llovet J.M., Bruix J.: Systematic
review of randomized trials for unre-
sectable hepatocellular carcinoma:
Chemoembolization improves sur-
vival. Hepatology, 2003, 37:429-442. 
11. Geschwind J.F., Ramsey D.E.,
Choti M.A., et al.: Chemo -
embolization of hepatocellular carci-
noma: results of metaanalysis. Am J
Clin Oncol, 2003, 26: 344-349.
12. Lo C.M., Ngam H., Tso W.K., et al.:
Randomized controlled trial of lipidol
chemoembolization for unresectable
hepatocellular carcinoma.
Hepatology, 2002, 35: 1164-1171.
13. Shen H. Agarwal D., QI R.,
Chalasani N.: Predictors of outcome
in patients with unresectable hepato-
cellular carcinoma receiving tran-
scatheter arterial chemoembolization.
Aliment pharmacol Ther, 2007, 26:
393-400.
14. Jinglin X., Zhenggang R.,
Shenglong Y., Sharma D, Zhiying L.,
Yuhong G., Yi C., Zengchen M.,
Zhiquan W., Jia F., Lunxiu Q.,
Xinda Z., Zhaoyou T., Binghui Y.: Study
of severe and rare complications of
transarterial chemoembolization
(TACE) for liver cancer. Euro J Rad,
2006, 59: 407-12.
15. Chung J.W., Park J.H., Han J.K., et al.:
Hepatic Tumors: Predisposing Factors
for Complications of transcatheter
oily chemoembolization. Radiology,
1996, 198: 33-40.
16. Sokamoto I., Aso N., Nagaoki K., et al:
Complications associated with
Transcatheter arterial embolization
for hepatic tumors. Radiographics,
1998, 18: 605-619.
17. Liu C.L., Ngan H., Lo C.M., et al.:
Ruptured hepatocellular carcinoma
as a complication of transarterial oily
chemomboliation. Br J Surg, 1998,
85:612-614.
18. Kim H.C., Yang D.M., Jin W., et al.: The
various manifestations of ruptured
hepatocellular carcinoma: CT imag-
ing findings. Abdom Imaging, 2008,
33: 633-642.
19. Battula N., Srinivasan P., Madanur M.,
et al.: Ruptured hepatocellular carci-
noma following chemoembolization:
a western experience. Hepatobiliary
Pancreat Dis Int, 2007, 6: 49-51.
performed to stabilize the tumor. In
ours opinion, emergency emboliza-
tion is an efficient haemostatic treat-
ment in case of intra-peritoneal
bleeding of a ruptured HCC. In this
particular situation of our patient
with a bad general health and the
absence of active bleeding, TACE or
embolization had to be excluded.
The only left solution was conserva-
tive management.
Although TACE is generally a safe
procedure, tumor rupture remains a
potential complication. As showed in
our patient, it appears to be especial-
ly important in large tumors adja-
cent to the liver capsule. In case of
such important masses, liver rupture
is a clear but relatively rare compli-
cation that may occur even in
absence of TACE. This complication
may appear relatively lately (several
weeks) after procedure, that the rea-
son why a precise follow-up is
mandatory.
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